{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T19:24:38Z","timestamp":1792783478717,"version":"4.5.0"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T00:00:00Z","timestamp":1792108800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T00:00:00Z","timestamp":1792108800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Universit\u00e4tsklinikum M\u00fcnster","id":[{"id":"https:\/\/ror.org\/01856cw59","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pediatr Drugs"],"DOI":"10.1007\/s40272-026-00780-3","type":"journal-article","created":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T01:25:59Z","timestamp":1792200359000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Isavuconazole: Real-World Data and Clinical Considerations for Pediatric Patients"],"prefix":"10.1007","author":[{"given":"Lorenzo","family":"Chiusaroli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danila","family":"Seidel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Ebrahimi-Fakhari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luise","family":"Martin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karoline","family":"Ehlert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1188-393X","authenticated-orcid":false,"given":"Andreas H.","family":"Groll","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zoi Dorothea","family":"Pana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,16]]},"reference":[{"key":"780_CR1","unstructured":"European Medicines Agency (EMA). Cresemba [Internet]. 2025 [cited 2025 May 14]. Available from: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/cresemba."},{"issue":"3","key":"780_CR2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1128\/AAC.01783-19","volume":"64","author":"N Decembrino","year":"2020","unstructured":"Decembrino N, Perruccio K, Zecca M, et al. A case series and literature review of isavuconazole use in pediatric patients with hemato-oncologic diseases and hematopoietic stem cell transplantation. Antimicrob Agents Chemother. 2020;64(3):1\u201310.","journal-title":"Antimicrob Agents Chemother"},{"key":"780_CR3","doi-asserted-by":"publisher","DOI":"10.1097\/MPH.0000000000001787","author":"JA Ross","year":"2020","unstructured":"Ross JA, Karras NA, Tegtmeier B, et al. Safety of isavuconazonium sulfate in pediatrics patients with hematologic malignancies and hematopoietic cell transplantation with invasive fungal infections: a real world experience. J Pediatr Hematol Oncol. 2020. https:\/\/doi.org\/10.1097\/MPH.0000000000001787.","journal-title":"J Pediatr Hematol Oncol"},{"key":"780_CR4","doi-asserted-by":"publisher","DOI":"10.1111\/myc.12731","author":"SC Mellinghoff","year":"2018","unstructured":"Mellinghoff SC, Bassetti M, D\u00f6rfel D, et al. Isavuconazole shortens the QTc interval. Mycoses. 2018. https:\/\/doi.org\/10.1111\/myc.12731.","journal-title":"Mycoses"},{"key":"780_CR5","doi-asserted-by":"publisher","DOI":"10.3390\/antibiotics10050487","author":"M Risum","year":"2021","unstructured":"Risum M, Vestergaard MB, Weinreich UM, et al. Therapeutic drug monitoring of isavuconazole: serum concentration variability and success rates for reaching target in comparison with voriconazole. Antibiotics (Basel). 2021. https:\/\/doi.org\/10.3390\/antibiotics10050487.","journal-title":"Antibiotics (Basel)"},{"key":"780_CR6","doi-asserted-by":"publisher","DOI":"10.1086\/590566","author":"BH Segal","year":"2008","unstructured":"Segal BH, Herbrecht R, Stevens DA, et al. Defining responses to therapy and study outcomes in clinical trials of invasive fungal diseases: Mycoses Study Group and European Organization for Research and Treatment of Cancer Consensus Criteria. Clin Infect Dis. 2008. https:\/\/doi.org\/10.1086\/590566.","journal-title":"Clin Infect Dis"},{"key":"780_CR7","doi-asserted-by":"crossref","unstructured":"Cornely OA, Hoenigl M, Lass-Fl\u00f6rl C, et al. Defining breakthrough invasive fungal infection\u2013position paper of the mycoses study group education and research consortium and the European Confederation of Medical Mycology. Mycoses. Blackwell Publishing Ltd; 2019. p. 716\u2013729.","DOI":"10.1111\/myc.12960"},{"key":"780_CR8","unstructured":"Medical Dictionary for Regulatory Activities. Common terminology criteria for adverse events (CTCAE) [Internet]. 2009. Available from: http:\/\/www.meddramsso.com."},{"issue":"8","key":"780_CR9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1128\/AAC.00290-21","volume":"65","author":"AC Arrieta","year":"2021","unstructured":"Arrieta AC, Neely M, Day JC, et al. Safety, tolerability, and population pharmacokinetics of intravenous and oral isavuconazonium sulfate in pediatric patients. Antimicrob Agents Chemother. 2021;65(8):1\u201312.","journal-title":"Antimicrob Agents Chemother"},{"key":"780_CR10","doi-asserted-by":"publisher","DOI":"10.1128\/aac.00484-24","author":"H Segers","year":"2024","unstructured":"Segers H, Deville JG, Muller WJ, et al. Safety, outcomes, and pharmacokinetics of isavuconazole as a treatment for invasive fungal diseases in pediatric patients: a non-comparative phase 2 trial. Antimicrob Agents Chemother. 2024. https:\/\/doi.org\/10.1128\/aac.00484-24.","journal-title":"Antimicrob Agents Chemother"},{"key":"780_CR11","unstructured":"European Medicines Agency (EMA). CRESEMBA, isavuconazole [Internet]. 2025 [cited 2025 Nov 18]. Available from: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/cresemba#:~:text=Cresemba%20is%20an%20antifungal%20medicine,amphotericin%20B%2C%20is%20not%20suitable."},{"key":"780_CR12","unstructured":"Food and Drug Administration (FDA). CRESEMBA\u00ae (isavuconazonium sulfate) [Internet]. 2025 [cited 2026 Jan 22]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2025\/207500s016,207501s016lbl.pdf."},{"key":"780_CR13","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.29807","author":"M Alali","year":"2023","unstructured":"Alali M, Balsara K, Khaitan A, et al. Successful isavuconazole salvage therapy for cerebral mucormycosis in a child with relapsed leukemia: a light in the dark tunnel. Pediatr Blood Cancer. 2023. https:\/\/doi.org\/10.1002\/pbc.29807.","journal-title":"Pediatr Blood Cancer"},{"issue":"8","key":"780_CR14","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1097\/INF.0000000000002671","volume":"39","author":"L Ashkenazi-Hoffnung","year":"2020","unstructured":"Ashkenazi-Hoffnung L, Bilavsky E, Levy I, et al. Isavuconazole as successful salvage therapy for mucormycosis in pediatric patients. Pediatr Infect Dis J. 2020;39(8):718\u201324.","journal-title":"Pediatr Infect Dis J"},{"key":"780_CR15","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.27281","author":"AA Barg","year":"2018","unstructured":"Barg AA, Malkiel S, Bartuv M, et al. Successful treatment of invasive mucormycosis with isavuconazole in pediatric patients. Pediatr Blood Cancer. 2018. https:\/\/doi.org\/10.1002\/pbc.27281.","journal-title":"Pediatr Blood Cancer"},{"issue":"10","key":"780_CR16","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1097\/INF.0000000000002418","volume":"38","author":"E Brivio","year":"2019","unstructured":"Brivio E, Verna M, Migliorino GM, et al. Isavuconazole-induced acute liver failure in a pediatric patient with invasive aspergillosis. Pediatr Infect Dis J. 2019;38(10):1035\u20137.","journal-title":"Pediatr Infect Dis J"},{"issue":"12","key":"780_CR17","doi-asserted-by":"publisher","first-page":"2886","DOI":"10.1093\/jac\/dkad324","volume":"78","author":"D Bury","year":"2023","unstructured":"Bury D, Wolfs TFW, Heine R, et al. Pharmacokinetic investigations of isavuconazole in paediatric cancer patients show reduced exposure of isavuconazole after opening capsules for administration via a nasogastric tube. J Antimicrob Chemother. 2023;78(12):2886\u20139.","journal-title":"J Antimicrob Chemother"},{"key":"780_CR18","doi-asserted-by":"crossref","unstructured":"Castagnola E, Mesini A, Saffioti C, et al. Intravenous isavuconazole can be administered 5 days-a-week. A possibility suggested by a real-life observation. J Chemotherapy. 2020; 32(4): 217\u201318.","DOI":"10.1080\/1120009X.2020.1755591"},{"issue":"1","key":"780_CR19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s40360-018-0273-7","volume":"19","author":"M Cornu","year":"2018","unstructured":"Cornu M, Bruno B, Loridant S, et al. Successful outcome of disseminated mucormycosis in a 3-year-old child suffering from acute leukaemia: the role of isavuconazole? A case report. BMC Pharmacol Toxicol. 2018;19(1):1\u20135.","journal-title":"BMC Pharmacol Toxicol"},{"issue":"6","key":"780_CR20","doi-asserted-by":"publisher","first-page":"E469","DOI":"10.1097\/MPH.0000000000001508","volume":"42","author":"F De Leonardis","year":"2020","unstructured":"De Leonardis F, Novielli C, Giannico B, et al. Isavuconazole treatment of cerebral and pulmonary aspergillosis in a pediatric patient with acute lymphoblastic leukemia: case report and review of literature. J Pediatr Hematol Oncol. 2020;42(6):E469\u201371.","journal-title":"J Pediatr Hematol Oncol"},{"key":"780_CR21","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics15010075","author":"H Elhence","year":"2023","unstructured":"Elhence H, Mongkolrattanothai K, Mohandas S, et al. Isavuconazole pharmacokinetics and pharmacodynamics in children. Pharmaceutics. 2023. https:\/\/doi.org\/10.3390\/pharmaceutics15010075.","journal-title":"Pharmaceutics"},{"issue":"8","key":"780_CR22","first-page":"863","volume":"26","author":"A Ferdjallah","year":"2021","unstructured":"Ferdjallah A, Nelson KM, Meyer K, et al. Isavuconazonium sulfate use in multi-modal management of invasive mucormycosis in four pediatric allogeneic hematopoietic cell transplant patients. J Pediatr Pharmacol Ther. 2021;26(8):863\u20137.","journal-title":"J Pediatr Pharmacol Ther"},{"issue":"3","key":"780_CR23","doi-asserted-by":"publisher","first-page":"E128","DOI":"10.1097\/INF.0000000000003017","volume":"40","author":"F Naeem","year":"2021","unstructured":"Naeem F, Laningham F, Kuzmic B, et al. Isavuconazole as salvage therapy for refractory pediatric coccidioidal meningitis. Pediatr Infect Dis J. 2021;40(3):E128\u201331.","journal-title":"Pediatr Infect Dis J"},{"key":"780_CR24","doi-asserted-by":"crossref","unstructured":"Garner LM, Echols CD, Wilson WS. Enteral tube administration of isavuconazole in a pediatric patient. Pediatr Blood Cancer. 2021;68(9):e29108.","DOI":"10.1002\/pbc.29108"},{"issue":"12","key":"780_CR25","doi-asserted-by":"publisher","DOI":"10.1128\/aac.00829-23","volume":"67","author":"B Fern\u00e1ndez Ledesma","year":"2023","unstructured":"Fern\u00e1ndez Ledesma B, Mendoza-Palomar N, Melendo P\u00e9rez S, et al. Isavuconazole use and TDM in real-world pediatric practice. Antimicrob Agents Chemother. 2023;67(12):e0082923.","journal-title":"Antimicrob Agents Chemother"},{"key":"780_CR26","doi-asserted-by":"crossref","unstructured":"Loeffen YGT, Scharloo F, Goemans BF, et al. Mucormycosis in children with hematologic malignancies: a case series and review of the literature. Pediatr Infect Dis J. 2022;41(9):E369\u201376.","DOI":"10.1097\/INF.0000000000003608"},{"key":"780_CR27","doi-asserted-by":"publisher","DOI":"10.3390\/jof7090726","author":"N Mendoza-Palomar","year":"2021","unstructured":"Mendoza-Palomar N, Melendo-P\u00e9rez S, Balcells J, et al. Influenza-associated disseminated aspergillosis in a 9-year-old girl requiring ECMO support. J Fungi. 2021. https:\/\/doi.org\/10.3390\/jof7090726.","journal-title":"J Fungi"},{"key":"780_CR28","doi-asserted-by":"publisher","DOI":"10.1016\/j.jiac.2024.07.018","author":"H Nemoto","year":"2025","unstructured":"Nemoto H, Hino M, Aoki T, et al. Effectiveness of isavuconazole in invasive cerebral aspergillosis during hematopoietic stem cell transplantation in a pediatric patient with myelodysplastic syndrome: a case report. J Infect Chemother. 2025. https:\/\/doi.org\/10.1016\/j.jiac.2024.07.018.","journal-title":"J Infect Chemother"},{"issue":"1","key":"780_CR29","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1007\/s11046-018-0287-0","volume":"184","author":"A Pomorska","year":"2019","unstructured":"Pomorska A, Malecka A, Jaworski R, et al. Isavuconazole in a successful combination treatment of disseminated mucormycosis in a child with acute lymphoblastic leukaemia and generalized haemochromatosis: a case report and review of the literature. Mycopathologia. 2019;184(1):81\u20138.","journal-title":"Mycopathologia"},{"key":"780_CR30","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.mmcr.2022.10.004","volume":"38","author":"H Shah","year":"2022","unstructured":"Shah H, Chisena E, Nguyen B, et al. Successful management of mucormycosis infection secondary to motor vehicle accident in a healthy adolescent: a case report. Med Mycol Case Rep. 2022;38:36\u201340.","journal-title":"Med Mycol Case Rep"},{"key":"780_CR31","doi-asserted-by":"crossref","unstructured":"Sosnowska-Sienkiewicz P, B\u0142aszczyk K, Kubisiak-Rzepczyk H, et al. How to treat a child with a concurrent diagnosis of leukemia and generalized mucormycosis? Case report. Front Med (Lausanne). 2022;9:844880.","DOI":"10.3389\/fmed.2022.844880"},{"issue":"2","key":"780_CR32","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1080\/10428194.2024.2416021","volume":"66","author":"J Styczynski","year":"2025","unstructured":"Styczynski J, Czyzewski K, Demidowicz E, et al. Isavuconazole in treatment of invasive fungal disease in children with malignancy or undergoing cellular therapy. Leuk Lymphoma. 2025;66(2):333\u20136.","journal-title":"Leuk Lymphoma"},{"issue":"3","key":"780_CR33","doi-asserted-by":"publisher","DOI":"10.3390\/ph15030375","volume":"15","author":"P Zimmermann","year":"2022","unstructured":"Zimmermann P, Brethon B, Roupret-Serzec J, et al. Isavuconazole treatment for invasive fungal infections in pediatric patients. Pharmaceuticals (Basel). 2022;15(3):375.","journal-title":"Pharmaceuticals (Basel)"},{"issue":"2","key":"780_CR34","doi-asserted-by":"publisher","first-page":"E143","DOI":"10.1097\/MPH.0000000000002812","volume":"46","author":"B Kunvarjee","year":"2024","unstructured":"Kunvarjee B, Siver M, Mathew S, et al. Characterization of the use and efficacy of isavuconazonium sulfate in a pediatric oncology and stem cell transplant population: a single institution retrospective review. J Pediatr Hematol Oncol. 2024;46(2):E143\u20136.","journal-title":"J Pediatr Hematol Oncol"},{"key":"780_CR35","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkaf394","author":"N Mendoza-Palomar","year":"2025","unstructured":"Mendoza-Palomar N, Sim\u00f3 Nebot S, Roig-Soria L, et al. Real-life use of isavuconazole in Spanish children and adolescents. J Antimicrob Chemother. 2025. https:\/\/doi.org\/10.1093\/jac\/dkaf394.","journal-title":"J Antimicrob Chemother"},{"issue":"6","key":"780_CR36","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1097\/FTD.0000000000000980","volume":"44","author":"M Gatti","year":"2022","unstructured":"Gatti M, Campoli C, Belotti T, et al. Real-world comparison of isavuconazole and voriconazole in terms of the need for dosage adjustments guided by clinical pharmacological advice during primary prophylaxis of invasive fungal infections in pediatric patients with hemato-oncological malignancies. Ther Drug Monit. 2022;44(6):641\u201350.","journal-title":"Ther Drug Monit"},{"key":"780_CR37","doi-asserted-by":"crossref","unstructured":"Casalini G, Giacomelli A, Antinori S. The WHO fungal priority pathogens list: a crucial reappraisal to review the prioritisation. Lancet Microbe. 2024;5(7):717\u201324.","DOI":"10.1016\/S2666-5247(24)00042-9"},{"key":"780_CR38","doi-asserted-by":"publisher","DOI":"10.1111\/tid.13469","author":"CA Vu","year":"2020","unstructured":"Vu CA, Rana MM, Jacobs SE, et al. Isavuconazole for the prophylaxis and treatment of invasive fungal disease: a single-center experience. Transplant Infect Dis. 2020. https:\/\/doi.org\/10.1111\/tid.13469.","journal-title":"Transplant Infect Dis"},{"key":"780_CR39","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-99-111727","author":"P Bose","year":"2018","unstructured":"Bose P, McCue D, Wiederhold NP, et al. Isavuconazole (ISAV) as primary anti-fungal prophylaxis in acute myeloid leukemia or myelodysplastic syndrome: an open-label, prospective study. Blood. 2018. https:\/\/doi.org\/10.1182\/blood-2018-99-111727.","journal-title":"Blood"},{"key":"780_CR40","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-025-02586-7","author":"L Pagano","year":"2025","unstructured":"Pagano L, Maschmeyer G, Lamoth F, et al. Primary antifungal prophylaxis in hematological malignancies. Updated clinical practice guidelines by the European Conference on Infections in Leukemia (ECIL). Leukemia. 2025. https:\/\/doi.org\/10.1038\/s41375-025-02586-7.","journal-title":"Leukemia"},{"issue":"10020","key":"780_CR41","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1016\/S0140-6736(15)01159-9","volume":"387","author":"JA Maertens","year":"2016","unstructured":"Maertens JA, Raad II, Marr KA, et al. Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi (SECURE): a phase 3, randomised-controlled, non-inferiority trial. Lancet. 2016;387(10020):760\u20139.","journal-title":"Lancet"},{"issue":"3","key":"780_CR42","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1093\/jac\/dky463","volume":"74","author":"T Kaindl","year":"2019","unstructured":"Kaindl T, Andes D, Engelhardt M, et al. Variability and exposure-response relationships of isavuconazole plasma concentrations in the Phase 3 SECURE trial of patients with invasive mould diseases. J Antimicrob Chemother. 2019;74(3):761\u20137.","journal-title":"J Antimicrob Chemother"},{"key":"780_CR43","unstructured":"NCT03816176 ClinicalTrials gov I. A phase 2, open-label, non-comparative, multicenter study to evaluate the safety and tolerability, efficacy and pharmacokinetics of isavuconazonium sulfate for the treatment of invasive aspergillosis (IA) or invasive mucormycosis (IM) in pediatric subject."},{"issue":"1","key":"780_CR44","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1002\/cpdd.284","volume":"6","author":"AH Groll","year":"2017","unstructured":"Groll AH, Desai A, Han D, et al. Pharmacokinetic assessment of drug-drug interactions of isavuconazole with the immunosuppressants cyclosporine, mycophenolic acid, prednisolone, sirolimus, and tacrolimus in healthy adults. Clin Pharmacol Drug Dev. 2017;6(1):76\u201385.","journal-title":"Clin Pharmacol Drug Dev"},{"key":"780_CR45","doi-asserted-by":"crossref","unstructured":"Lehrnbecher T, Fisher BT, Phillips B, et al. Clinical practice guideline for systemic antifungal prophylaxis in pediatric patients with cancer and hematopoietic stem-cell transplantation recipients. J Clin Oncol. 2020;38(27):3205-16","DOI":"10.1200\/JCO.20.00158"}],"container-title":["Pediatric Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40272-026-00780-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40272-026-00780-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40272-026-00780-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T01:26:01Z","timestamp":1792200361000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40272-026-00780-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,16]]},"references-count":45,"alternative-id":["780"],"URL":"https:\/\/doi.org\/10.1007\/s40272-026-00780-3","relation":{},"ISSN":["1174-5878","1179-2019"],"issn-type":[{"value":"1174-5878","type":"print"},{"value":"1179-2019","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,16]]},"assertion":[{"value":"10 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A.H. Groll has received grants from Gilead; served as a consultant to Basilea, Mundipharma, and Pfizer; received payment or honoraria from Basilea, Gilead, Merck, Merck Sharp & Dohme, Mundipharma, Novartis, and Pfizer; received payment for expert testimony from Mundipharma and Pfizer; and participated in the Safety Monitoring Board or Advisory Board for Astellas. The other authors declare that they have no conflict of interest.","order":1,"name":"Ethics","label":"Conflict of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"During the preparation of this manuscript, the authors used [Claude\/Gemini] solely to improve the clarity and grammatical correctness of the English language in selected sentences. The tool was not used to generate, analyze, or interpret data, nor to draft scientific content, conclusions, or references. After using this tool, the authors have reviewed and edited all text as needed and all authors take full responsibility for the content of the publication.","order":2,"name":"Ethics","label":"Use of Artificial Intelligence (AI)","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Data are contained within the article.","order":3,"name":"Ethics","label":"Availability of Data and Material","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethical approval not applicable for the type of study. The study was performed in accordance with the ethical standards as laid down in the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards.","order":4,"name":"Ethics","label":"Ethics Approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":5,"name":"Ethics","label":"Consent to Participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":6,"name":"Ethics","label":"Consent for Publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":7,"name":"Ethics","label":"Code Availability","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"A.G. and Z.D.P. conceived the presented review; L.C. and L.M. contributed to the literature search, screened literature for study selection, and conducted data collection; L.C., A.G., and Z.D.P. study selection; L.C. performed formal analysis and wrote the first draft of the manuscript with input from all authors; L.C., A.G, K.L., L.M., D.E.F, D.S. and Z.D.P. aided in interpreting the results and revised the manuscript. All authors have read and agreed to the published version of the manuscript.","order":8,"name":"Ethics","label":"Author Contributions","group":{"name":"EthicsHeading","label":"Declarations"}}]}}